We would love to hear your thoughts about our site and services, please take our survey here.
"Boosters every 3 to 6 months seem to be required for first generation vaccines again for 7 billion people which is very expensive and logistically impossible."
7 billion seconds is 220 years I doubt they can make a dose every second much less ship it and inject it. The idea that there should be world-wide boosters every 6 months is laughable. Jabbing the 70m population of the UK at 1 per second, day in day out would take over 2 years
I rather imagine there is a finger on top of the first domino just waiting to give it the flick required to start all the other dominoes . Will the agm be the start of the chain reaction or will it be the first tranch of covidity results or maybe they are one and the same? I really dont see RM being happy with a bag or two on their investment knowing the size of the prize if all goes to a fairly simple plan. The potential here is huge, the IP is well protected and the problems that the technology might fix are only getting worse. And if the technology does work as anticipated the savings for healthcare would be huge too. We spend something like £15Bn a year in the UK on cancer care alone.
Interesting discussion this evening chaps. One thing that jumps out at me is how "risk-off" the UK investment companies seem to be in comparison with our American cousins. There are loads of small UK companies with great problem -solving science that end up going nowhere because the UK seems incapable of being able to spot them and ultimately back them with the sorts of cash required. Its been a UK story for far too long ... science done in the UK profits made in the US . The lack of scientists in politics and business is a huge problem that needs addressing.
https://trialsitenews.com/european-study-alpha-variant-likely-evading-vaccines-wreaking-havoc-in-europe/?utm_source=Contextly&utm_medium=ChannelEmail&utm_campaign=SARS-CoV-2&utm_content=Notification
"The novel B.1.1.7 sub-lineage includes mutations of nucleoprotein G204P"
Yesterday's Budget included $8.24Bn for the NHS to improve its use of technology including the building of 100 scanning centres. Putting IQAI technology into 100 scanning centres would seem to be a complete " no brainer" . At £100k per year per centre it would add £10m a year to turnover and probably save at least that much in reduced costs for the NHS and thats just for the new centres. When you add on existing scanning centres and hospitals in the UK ........double , triple that? More? And thats just the UK !
Its hard to imagine CEPI would just announce a company out of the blue, there would surely be a round of talks to ensure everyone is on the same page prior to an announcement. The expansion of lab space and increasing numbers of staff may be a precursor to an announcement simply to give the project its best chance of early success. The CEPI decision may have been taken weeks ago with the announcement timing being decided to suit both or all parties. NDAs will have been signed, Heads of agreement signed etc. The last thing needed is an announcement that then gets rowed back because of disagreement due to a lack of planning.
Summary
Although both infections and vaccines induce memory B cell (MBC) populations that participate in secondary immune responses, the MBCs generated in each case can differ. Here, we compare SARS-CoV-2 spike receptor binding domain (S1-RBD)-specific primary MBCs that form in response to infection or a single mRNA vaccination. Both primary MBC populations have similar frequencies in the blood and respond to a second S1-RBD exposure by rapidly producing plasmablasts with an abundant immunoglobulin (Ig)A+ subset and secondary MBCs that are mostly IgG+ and cross-react with the B.1.351 variant. However, infection-induced primary MBCs have better antigen-binding capacity and generate more plasmablasts and secondary MBCs of the classical and atypical subsets than do vaccine-induced primary MBCs. Our results suggest that infection-induced primary MBCs have undergone more affinity maturation than vaccine-induced primary MBCs and produce more robust secondary responses.
https://www.cell.com/cell-reports/fulltext/S2211-1247(21)01287-0
As you were! Normal service continues uninterrupted. A (very) brief rush of excitement was quickly damped down. Does anyone else think the RNS should have been embargoed until this morning and someone ****ed up? Just me? Oh well back to snoozing.
Maybe they dont think that the start is newsworthy and we will only get notification of the results?
I dont think scientists ever pay much attention to the shareprice whilst they are busy doing scientific stuff ?
Sorry posted below before adding link
https://www.ukcolumn.org/article/stabilising-the-code
I have no idea if this is a fact or speculation but it is more than a little worrying and plausible. It would be helpful if anyone has any thoughts.
Changes to key parts of the mRNA code in SARS-CoV-2 vaccines may be causal in changing the innate immune response via toll-like receptors. Toll-like receptors are important components in defence against infection and downstream effects may also include inhibition of CD8 T cell response. CD8 is a vital part of the immune system’s ability to eradicate infection and cancer. Those changes may be reflected in recent reactivated Varicella Zoster infections although specific mechanisms are unclear at the moment. Anecdotal reports of significant uptick in cancer presenting to medical consultants may be consistent with aberrant toll-like receptor and dendritic cell changes leading to an inhibition of the anti-cancer CD8 effector response. Further data are required but the prospect of an altered CD8 response to infection and cancer is very concerning and should prompt urgent investigation.
Would they need to g into another set of trials if they were to introduce the Pharmajet system at a later date? If so it makes scientific sense to wait but, are people who are desperate for their cancer to be cured going to be bothered by which delivery system is used? Perhaps getting to market with a product which is "good enough" and better than other current treatments might be a better strategy than more delay and a slightly better product?
Maybe the reason that Lindy felt able to become the CEO is that she now has a team she trusts to continue the work she has started. There is more than enough science in the locker, the need is to now get the data from trials, not to continue developing new additions to the technology. Maybe, being able to focus more on the business will also give Lindy some headspace to come up with more genius science ideas and the money to persue them. I think she knows that getting the current list of products into the market is the main requirement , I would bet she already knows what to do with any major influx of cash.
I too think the recent sales have been people hedging their investment bet, by selling 25, 30% ahead of pending news and settling for reinvesting at a somewhat higher price assuming the news is positive enough to raise the price.
Seems to me that we are suffering from a lack of news because of some sort of due diligence taking place. We only find anything out from the persistent digging of shareholders that post their findings. The Company has been effectively silent on its products and their scientific advancement for months, much less their commercial advancement.
This new company, could it be that they are thinking of taking non-cancer vaccines a bit more seriously, perhaps at the behest of CEPI? Could the Nottingham collaborations be part of the thinking?.. Press ahead with the Scancell Cancer products whilst developing a range of other vaccines with alternative delivery systems and targeted at CEPI's stated list of problems they would like to be prepared for and have solutions for? If Covidity helps to solve the Coronavirus problems around the world, maybe the knocking on the door will get louder and having a specialist Vaccines vehicle is deemed easier than rocking the boat just as its getting into its stride with so many Cancer possibilities? And presumably it gives the IIs another bite at the cherry? What else could they target where T cell activation could be key?.
CEPI LIst: https://cepi.net/research_dev/priority-diseases/
Its aa bit less the size of a football pitch ..."For international matches the dimensions must be between 110-120 yards (100-110 meters) long and 70-80 yards (64-75m) wide"
Unfortunately, when there is an information vacuum, people fill the void with supposition. The companies investors would be less likely to make 2+2 =22 from scraps of internet information from sources doing exactly the same thing if the company would undertake to produce a quarterly update that investors could rely on for at least some reliable information on the various platforms we have helped to fund, new people on board etc. Even if the updates said that there is nothing new to add except forward momentum of the science. At the moment we are very much in the dark and we need to be allowed to see a pinpoint of light at the end of the tunnel if not the actual end of the tunnel.
“We wait. We are bored. (He throws up his hand.) No, don't protest, we are bored to death, there's no denying it. Good. A diversion comes along and what do we do? We let it go to waste. Come, let's get to work! (He advances towards the heap, stops in his stride.) In an instant all will vanish and we'll be alone more, in the midst of nothingness!”
? Samuel Beckett, Waiting for Godot .... or perhaps Waiting for Scancell!